Scholarlink

Background <p>Trigeminal neuralgia (TN) caused by vertebrobasilar dolichoectasia (VBD) is a rare but particularly challenging entity. Microvascular decompression (MVD) is considered the most definitive treatment; however, outcomes in this subgroup remain incompletely characterized.</p> Methods <p>We conducted a systematic review and meta-analysis following PRISMA guidelines. PubMed, Embase, Scopus, and Web of Science were searched from inception through August 22, 2025. Eligible studies reported on patients with VBD-TN undergoing MVD with extractable data on pain outcomes, recurrence, salvage interventions, or complications. Complete relief was defined as Barrow Neurological Institute (BNI)-I, while adequate relief included BNI-I to IIIb.</p> Results <p>Thirteen studies involving 315 patients were analyzed. The mean age ranged from 54.0 to 67.3&#xa0;years, with 57.8% (182/315) being males. The pooled initial complete pain relief rate was 95.8% (95% CI, 92.3–98.2), with sustained relief at the last follow-up in 92.6% (95% CI, 88.4–96.1). Adequate relief was nearly universal, at 99.9% (95% CI, 98.2–100%) initially and 95.9% (95% CI, 91.8–98.8%) at the last follow-up. Pain recurrence occurred in 5.5% (95% CI, 2.9–8.9%), and salvage procedures were required in 1.3% (95% CI, 0.2–3.1%). The permanent morbidity was low at 2.4% (95% CI, 0.8–4.8%). Meta-regression indicated that prior ablative procedures were associated with higher complication rates, whereas V2 involvement predicted better long-term pain control.</p> Conclusion <p>MVD appears to provide effective and durable pain relief for selected patients with VBD-TN, with low permanent morbidity but a clinically meaningful overall complication burden. Given the retrospective nature of the available evidence, MVD should be considered a promising treatment option rather than a definitive standard of care.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Microvascular decompression for trigeminal neuralgia secondary to vertebrobasilar dolichoectasia: a systematic review and meta-analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月28日

查看全文
  • Bardia Hajikarimloo,
  • Ibrahim Mohammadzadeh,
  • Salem M. Tos,
  • Mohammad Amin Habibi,
  • Mohammadmahdi Sabahi,
  • Badih Adada,
  • Hamid Borghei-Razavi

摘要

Background

Trigeminal neuralgia (TN) caused by vertebrobasilar dolichoectasia (VBD) is a rare but particularly challenging entity. Microvascular decompression (MVD) is considered the most definitive treatment; however, outcomes in this subgroup remain incompletely characterized.

Methods

We conducted a systematic review and meta-analysis following PRISMA guidelines. PubMed, Embase, Scopus, and Web of Science were searched from inception through August 22, 2025. Eligible studies reported on patients with VBD-TN undergoing MVD with extractable data on pain outcomes, recurrence, salvage interventions, or complications. Complete relief was defined as Barrow Neurological Institute (BNI)-I, while adequate relief included BNI-I to IIIb.

Results

Thirteen studies involving 315 patients were analyzed. The mean age ranged from 54.0 to 67.3 years, with 57.8% (182/315) being males. The pooled initial complete pain relief rate was 95.8% (95% CI, 92.3–98.2), with sustained relief at the last follow-up in 92.6% (95% CI, 88.4–96.1). Adequate relief was nearly universal, at 99.9% (95% CI, 98.2–100%) initially and 95.9% (95% CI, 91.8–98.8%) at the last follow-up. Pain recurrence occurred in 5.5% (95% CI, 2.9–8.9%), and salvage procedures were required in 1.3% (95% CI, 0.2–3.1%). The permanent morbidity was low at 2.4% (95% CI, 0.8–4.8%). Meta-regression indicated that prior ablative procedures were associated with higher complication rates, whereas V2 involvement predicted better long-term pain control.

Conclusion

MVD appears to provide effective and durable pain relief for selected patients with VBD-TN, with low permanent morbidity but a clinically meaningful overall complication burden. Given the retrospective nature of the available evidence, MVD should be considered a promising treatment option rather than a definitive standard of care.